• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173360 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
% M6 `1 p/ m+ z2 k; ?/ {% T% u+ j
$ S! h9 a5 j8 Y- L, H( K
Sub-category:
" A- M1 J, u* P% z3 w$ WMolecular Targets 2 r  _$ i6 s* H* Q

8 H  x4 o0 H7 x0 m4 f. e4 v# l# a$ ]9 K- T$ C
Category:
6 G1 P5 M  B9 }4 g7 LTumor Biology 7 B+ P* M/ M! o" u( e

" T, t2 S  r" d6 |& G4 T) Z4 D+ j% H6 J6 c, g% N
Meeting:1 J& u% w! }; `1 c4 I2 }# {
2011 ASCO Annual Meeting , {$ y& V5 Z, W# W

( l/ W; q  N3 ~# W: R3 H! u# }+ ?- I& i
Session Type and Session Title:
( V7 D+ b  m) L" X3 \# JPoster Discussion Session, Tumor Biology 7 R" G" I5 y, u$ U; b. o
4 X% T- F& H6 D( a4 s
) U3 D/ [5 U+ n: u% Q
Abstract No:4 ]$ _+ u7 j; {4 A  W" F5 d
10517
3 Q1 n! j! w0 Y" Z8 m4 Y
( Y$ X' t+ |4 C+ T. J9 M# o/ B  J8 {* A& I# e% @
Citation:1 M# D  F, l) s; c: ^; T
J Clin Oncol 29: 2011 (suppl; abstr 10517) / m% B+ z" u6 J3 v( r" n0 u# {- A9 _

8 S- }( O$ C' ?5 q; m1 @& I) i7 B7 a  V4 h) `# J6 E8 K
Author(s):; n! A* L" J) v8 |5 K# c0 x; P9 d- e
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ' }  ^7 k0 ~  E& B4 @% Y

; d2 d0 X+ j: y6 n4 p" e" x9 b9 D- T, O; r! N; ~3 b
, ^+ r6 W* l  K  i3 V2 Q2 T. m: X
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& a. b; p  R' W! z0 |* _# W" i6 P, o
Abstract Disclosures- r8 \6 z) ]+ M0 {

' K' X2 Q* P) a. IAbstract:
- H6 b7 S2 ^' Z' O- x) n) U8 A* K# u( U7 p7 j0 \3 B3 o

" @( A9 ?5 w. aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
+ k' L, M2 M1 ?& m" d# }( C. R; j2 ^1 e+ A8 y
% I: i8 \% o& O0 r3 g
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37   p+ H* ?5 Y7 Y
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
5 K& ?8 r$ u  m
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
) b" S4 s  C- |0 k! _/ w易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。6 E0 @) j2 h9 L
ALK一个指标医院要900多 ...
: X  b6 r' z$ q! h; P/ B
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
( J- q. ^& P/ D5 `# C! ~2 b1 O+ m5 d# P$ I2 h
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表